Fundz

Novanta

Bedford, Massachusetts, United States · Information Technology, Manufacturing, Other

Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers (“OEMs”) a competitive advantage. We combine deep proprietary technology expertise and competencies in photonics, vision and precision motion with a proven ability to solve complex technical challenges. This enables Novanta to engineer core components and sub

Key facts

Headquarters
Bedford, Massachusetts, United States
Employees
3,000
Industries
Information Technology, Manufacturing, Other
Status
Public (NOVT)
Website
novanta.com
LinkedIn
Company page

Recent activity at Novanta

  • : SEC 8-K (2.01): On July 23, 2026, Novanta Inc. completed the acquisition of Runway Buyer, LLC, a wholly owned subsidiary of Runway Midco, LLC, for approximately $1.2 billion in cash, with an additional milestone payment of $250 million due by January 8, 2027. The transaction involved several parties, including Novanta Medical Technologies Corp. as the buyer and Runway Midco, LLC as the seller. The acquisition is expected to significantly enhance Novanta's market position and operational capabilities. This acquisition was funded through a combination of cash on hand and a $616 million borrowing under their credit facilities, as previously detailed in earlier filings.
  • : Novanta Inc. acquires Riverpoint Medical for $1.2B
  • : Novanta Inc. raises $300 million in a private placement with institutional investors. The funding is expected to close around June 11, 2026.
  • : SEC 8-K (1.01): On June 8, 2026, the Company entered into a Securities Purchase Agreement for a private placement with institutional and other accredited investors, termed Purchasers. This agreement outlines the purchase of 2,142,857 common shares at $140.00 per share, amounting to approximately $300.0 million. The closing is anticipated to occur on June 11, 2026, contingent on customary closing conditions. Additionally, a Registration Rights Agreement was executed, obligating the Company to register the resale of shares and file a registration statement with the SEC within 30 days post-closing, ensuring compliance with the Securities Act. The transaction aims to expand the Company's shareholder base significantly and strengthen its capital structure.
  • : SEC 8-K (1.01): On June 8, 2026, Novanta Inc., along with its indirect subsidiary Novanta Medical Technologies Corp. and other affiliated parties, entered into an Equity Purchase Agreement to acquire all the issued and outstanding limited liability company interests of Runway Buyer, a subsidiary of Runway Midco, LLC, for a total consideration of $1.2 billion in cash. Additionally, a milestone payment of $250 million is set to be paid by January 8, 2027, subject to various customary conditions including regulatory approvals and financial adjustments at closing. The transaction is expected to be financed through cash on hand, existing credit facilities, and proceeds from a new equity issuance announced concurrently. This acquisition marks a significant strategic move for Novanta, expanding its operations in the medical technologies sector.
  • : SEC 8-K (1.01): On May 15, 2026, Novanta Inc. entered into the Second Amendment to its Fourth Amended and Restated Credit Agreement, in collaboration with Bank of America and other lenders. This amendment establishes $200.0 million of delayed draw term loan commitments, available for borrowing for six months post-effective date. The loans have various interest rates based on the company's leverage ratio, with a maturity date of June 27, 2030. The agreement includes terms for quarterly amortization starting September 2026 and resets certain commitment capacities. This move enhances Novanta's liquidity and financial framework ahead of future expenditures.
  • : Novanta Inc. Appoints Alexander Manganiello as General Counsel and Corporate Secretary
  • : SEC 8-K (7.01): Effective December 1, 2025, Novanta Inc. appointed Alexander Manganiello as General Counsel and Corporate Secretary. Mr. Manganiello has 30 years of experience with global public companies, including his most recent role as Vice President, Deputy General Counsel at Vertex Pharmaceuticals. His responsibilities will include overseeing the Company's global legal, regulatory, corporate secretary, and trade compliance organizations. This appointment reflects Novanta's strategic focus on enhancing its legal and compliance capabilities, essential for navigating complex global regulations.
  • : SEC 8-K (7.01): On December 1, 2025, Novanta Inc. appointed Alexander Manganiello as General Counsel and Corporate Secretary. In this role, he will lead the Company’s global legal and regulatory teams, bringing over 30 years of experience in legal counsel from previous positions, including Vice President at Vertex Pharmaceuticals and various roles at Pfizer. His appointment reflects a strategic move to enhance the legal and compliance capabilities of Novanta as it continues to expand its operations globally. This change is effective immediately, indicating a fast-tracked approach to strengthening the legal framework within the company.
  • : SEC 8-K (7.01):

Novanta funding history

DateRoundAmount
Jun 2026Post-IPO Equity$300.0M

Leadership

  • Jamie Sweeney, Senior Director of Global Talent Acquisition
  • Rebecca Dunne, Principal Talent Acquisition Partner
  • John Lesica, Co-Chief Operating Officer
  • Alexander Manganiello, General Counsel

Verified email and direct lines for Novanta’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Employee benefit plans

Novanta files 5 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Novanta in the news

Companies similar to Novanta

About Novanta: questions and answers

What does Novanta do?

Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers (“OEMs”) a competitive advantage. We combine deep proprietary technology expertise and competencies in photonics, vision and precision motion with a proven ability to solve complex technical challenges. This enables Novanta to engineer core components and sub

Where is Novanta headquartered?

Novanta is headquartered in Bedford, Massachusetts, United States.

How many employees does Novanta have?

Novanta has about 3,000 employees.

Has Novanta raised funding?

Yes. Fundz has recorded 1 funding event for Novanta. The most recent, Post-IPO Equity of $300.0M, was in Jun 2026.

What is the latest news on Novanta?

On Jul 27, 2026, SEC 8-K (2.01): On July 23, 2026, Novanta Inc. completed the acquisition of Runway Buyer, LLC, a wholly owned subsidiary of Runway Midco, LLC, for approximately $1.2 billion in cash, with an additional milestone payment of $250 million due by January 8, 2027. The transaction involved several parties

Is Novanta a public company?

Yes. Novanta is publicly traded under the ticker NOVT.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Novanta across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.